It is not known whether or not the FIGHT-202 trial for pemigatinib included patients with drusen in their study, as their exclusion criteria included patients with ‘clinically significant retinal disorders.’ The importance of preexisting RPE alterations is likely highlighted in the proposed mechanism of SRF development in FGFR- and MEK-induced retinopathy. Here, MAP2K7 is linked to retinal disorder.